Tranche Update on Jointown Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on June 18, 2024.

Published on 10/08/2024 at 18:00

S&P Capital IQ

-0.37%

From July 1, 2024 to September 30, 2024, the company has repurchased 36,820,500 shares, representing 0.78% for CNY 171.97 million. With this, the company has completed the repurchase of 55,470,500 shares, representing 1.16% for CNY 265.02 million under the buyback announced on June 18, 2024.

Latest news about Jointown Pharmaceutical Group Co., Ltd

Jointown Pharmaceutical Gets Drug Registration for Betamethasone Sodium Phosphate Injection	Jun. 06	MT
Jointown to Invest 23 Million Yuan Into Pharma-Focused Investment Fund	May. 19	MT
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 28	CI
Jointown Pharmaceutical Group Raises 826 Million Yuan from Completion of Private Equity Fund	Apr. 17	MT
Jointown Pharmaceutical Group Obtains Market Authorization for Cholesterol-Lowering Drug	Mar. 19	MT
Jointown Pharmaceutical Says China Universal Healthcare REIT Raises 1.16 Billion Yuan From Offering	Feb. 13	MT
Jiuzhoutong Pharmaceutical Receives CSRC Approval for REITs	Dec. 25	MT
Jointown Pharmaceutical Unit Gets Drug Ingredient Approval for Liver Dysfunction Treatment	Dec. 23	MT
BGM Group Ltd and Jointown Pharmaceutical Group Deepen Cooperation, Ushering in a New Era of Pharmaceutical Development	Dec. 19	CI
Jointown Pharmaceutical Group to Cut Jiuzhoutong Pharmaceutical Investment's Capital to 526 Million Yuan	Dec. 18	MT
Jointown Pharmaceutical Group Plans to Transfer Jiuzhou Shourui Equity to Public Infrastructure REITs	Dec. 18	MT
Jointown Pharmaceutical Plans Transfer of Assets in Shanghai, Hangzhou, Chongqing	Dec. 18	MT
Tranche Update on Jointown Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on June 18, 2024.	Dec. 17	CI
Jointown Pharmaceutical Group Co., Ltd's Equity Buyback announced on June 18, 2024, has expired with 56,036,500 shares, representing 1.17% for CNY 268.1 million.	Dec. 15	CI
Hangzhou Jiuyuan Gene Engineering Launches Up to HK$570 Million Hong Kong IPO	Nov. 19	MT
Jointown Pharmaceutical's Q3 Profit Rises 2%, Operating Income Climbs 4%	24-10-29	MT
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-28	CI
Jointown Pharmaceutical General Manager Steps Down	24-10-16	MT
Tranche Update on Jointown Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on June 18, 2024.	24-10-08	CI
Weimai Medical Technology Co., Ltd. announced that it has received funding from Jointown Pharmaceutical Group Co., Ltd, Shenzhen Qianhai BangQin Investment Co., Ltd., Shanghai Dinghui Baifu Investment Management Co., Ltd.	24-09-26	CI
China Approves Jointown Unit's Active Pharmaceutical Ingredient Application for Edema Drug; Shares Fall 3%	24-09-12	MT
Jointown Pharmaceutical Group's H1 Attributable Profit Slides 10%	24-08-27	MT
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-21	CI
Jointown Pharmaceutical Group Co., Ltd announced that it has received CNY 1.79 billion in funding	24-08-18	CI
Jointown Pharmaceutical Issues 1 Billion Yuan Asset-Backed Bonds	24-07-22	MT